Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands, and Anti-CD40 Antibody (MBTA)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60076658%3A12310%2F20%3A43901362" target="_blank" >RIV/60076658:12310/20:43901362 - isvavai.cz</a>
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202000044" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202000044</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/adtp.202000044" target="_blank" >10.1002/adtp.202000044</a>
Alternative languages
Result language
angličtina
Original language name
Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands, and Anti-CD40 Antibody (MBTA)
Original language description
Emerging evidence is demonstrating the extent of T-cell infiltration within the tumor microenvironment has favorable prognostic and therapeutic implications. Hence, immunotherapeutic strategies that augment the T-cell signature of tumors hold promising therapeutic potential. Recently, immunotherapy based on intratumoral injection of mannan-BAM, toll-like receptor ligands and anti-CD40 antibody (MBTA) demonstrated promising potential to modulate the immune phenotype of injected tumors. The strategy promotes the phagocytosis of tumor cells to facilitate the recognition of tumor antigens and induce a tumor-specific adaptive immune response. Using a syngeneic colon carcinoma model, MBTA's potential to augment CD8(+) T-cell tumor infiltrate when administered intratumorally or subcutaneously is demonstrated as part of a whole tumor cell vaccine. Both immunotherapeutic strategies prove effective at controlling tumor growth, prolong survival, and induce immunological memory against the parental cell line. Collectively, the investigation demonstrates MBTA's potential to trigger a potent anti-tumor immune response.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Advanced Therapeutics
ISSN
2366-3987
e-ISSN
—
Volume of the periodical
3
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
15
Pages from-to
—
UT code for WoS article
000539593800001
EID of the result in the Scopus database
2-s2.0-85102986557